Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $982.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by Truist Financial from $780.00 to $982.00 in a research report report published on Monday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the company. Citigroup boosted their price objective on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a report on Friday, October 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. TD Cowen increased their target price on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Leerink Partners boosted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals Stock Down 4.4%

Shares of REGN opened at $930.67 on Monday. The company has a market cap of $95.82 billion, a PE ratio of 20.38, a P/E/G ratio of 1.45 and a beta of 0.10. The business has a fifty day moving average of $800.69 and a 200 day moving average of $741.11. Regeneron Pharmaceuticals has a 52-week low of $591.52 and a 52-week high of $991.73. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the previous year, the business posted $11.83 earnings per share. The business’s revenue was up 36.3% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 51.64 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the transaction, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph Larosa sold 4,466 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the transaction, the executive vice president directly owned 38,906 shares in the company, valued at $37,563,353.94. This trade represents a 10.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 20,789 shares of company stock worth $18,766,698 over the last quarter. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. LCM Capital Management Inc boosted its position in Regeneron Pharmaceuticals by 2.2% during the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 13 shares in the last quarter. Arjuna Capital increased its holdings in shares of Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares during the period. Oakworth Capital Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 25.0% in the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 14 shares during the period. Geneos Wealth Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after acquiring an additional 15 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 16 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.